Arch Biopartners Inc.

Company Profile

Sector

Healthcare

Industry

Biotechnology

Employees

N/A

Website

www.archbiopartners.com

Country

Canada

Exchange

TSXV

Arch Biopartners develops novel drugs for acute kidney injury and organ damage in Canada. It focuses on developing its lead drug candidate LSALT Peptide, which is in Phase 2 trials to treat inflammation related acute kidney injury experienced by patients undergoing on-pump (bypass) cardiac surgery

Cilastatin to prevent toxin related acute kidney injury via dipeptidase-1. It also develops CKD Platform, therapeutics targeting chronic kidney disease. Arch Biopartners Inc. is based in Toronto, Canada.

Key Stats

52-Week Range

C$0.39C$1.75

Beta1.76

Trailing P/EN/A

Forward P/EN/A

Trailing EPS-0.04

Avg Volume

Earnings & Analyst

Next Earnings2026-08-28

EPS EstimateN/A

Target Mean PriceN/A

RecommendationNone

Recommendation MeanN/A

Recent SEC Filings

SEC filings for this ticker are not available yet.